Phase IB/II Open-label Single Arm Study to Evaluate Safety and Efficacy of Tucatinib in Combination With Palbociclib and Letrozole in Subjects With Hormone Receptor Positive and HER2-positive Metastatic Breast Cancer
收藏DataCite Commons2025-06-01 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00009028/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
This is a multicenter run-in phase Ib / roll-over phase II study of triple targeted drug
combination (HER2-targeted small molecule inhibitor tucatinib, CDK4/6 inhibitor palbociclib
and aromatase inhibitor letrozole) as a first or second line of therapy in patients with
metastatic hormone receptor positive and HER2-positive breast cancer.
提供机构：
Vivli
创建时间：
2023-06-21
